Samsung Biologics and ImmuneOncia sign multi-product development and manufacturing agreement

Corporate Breaking News

Home : Samsung Biologics and ImmuneOncia sign multi-product development and manufacturing agreement

Jul 15 2020	Samsung Biologics and ImmuneOncia sign multi-product development and manufacturing agreement
SONGDO, South Korea, July 15, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics held a signing ceremony today for a contract to develop and manufacture five candidate molecules, expanding upon the two companies' existing CDO partnership first established in...


Source:https://www.prnewswire.com:443/news-releases/samsung-biologics-and-immuneoncia-sign-multi-product-development-and-manufacturing-agreement-301093634.html

Related News
» Yunqi founding partner Michael Mao calls on fintech start-ups to safeguard boundaries and create long-term value as three of its angel-round invested companies are included in CB Insights List » 37 Interactive Entertainment adopted the United Nations Women's Empowerment Principles and committed to promote gender equality